Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 31

Sort by

Sort Order Select

Journal Articles

Prospective comparison of outcomes with azacitidine and decitabine in patients with AML ineligible for intensive chemotherapy

Blood (2022) 140 (3): 285–289.

https://doi.org/10.1182/blood.2022015832

Published: 2022

Includes: Supplemental data

Journal Articles

Genetic Determinants of Response to Guadecitabine (SGI-110) in AML

Patricia L. Kropf, MD, Woonbok Chung, PhD, Andrew D. Kelly, BA, Hagop M. Kantarjian, MD, Gail J. Roboz, Karen W.L. Yee, MD, Pietro Taverna, PhD, Sue Naim, Mohammad Azab, MD, Jaroslav Jelinek, MD PhD, Jean-Pierre J. Issa, MD

Blood (2016) 128 (22): 1680.

https://doi.org/10.1182/blood.V128.22.1680.1680

Published: 2016

Journal Articles

Improved Survival for MDS/CMML Patients Treated with the Combination of Decitabine (DAC) and Arsenic Trioxide (ATO) in a Phase II Adaptive Three Arm Randomization Study: DAC Alone Vs. DAC +/- Carboplatin or ATO

Patricia L. Kropf, MD, Raji Shameem, MD, Philip A. Pancari, MD, Henry Fung, MD, Lianchun Xiao, PhD, Xuelin Huang, PhD, Woonbok Chung, PhD, Hagop M. Kantarjian, MD, Jean-Pierre J. Issa, MD

Blood (2016) 128 (22): 3170.

https://doi.org/10.1182/blood.V128.22.3170.3170

Published: 2016

Journal Articles

Reactivation of the X-Chromosome Genes within PV Clone

Soo Jin Kim, MS, Jaroslav Jelinek, MD PhD, Jean-Pierre J Issa, MD, Josef T. Prchal, MD, Sabina Swierczek, PhD

Blood (2015) 126 (23): 4086.

https://doi.org/10.1182/blood.V126.23.4086.4086

Published: 2015

Journal Articles

The myelodysplastic syndrome as a prototypical epigenetic disease

Jean-Pierre J. Issa

Blood (2013) 121 (19): 3811–3817.

https://doi.org/10.1182/blood-2013-02-451757

Published: 2013

Journal Articles

Sequential Therapy with Allogeneic Transplant Followed by Low-Dose Azacitidine for CML Patients That Failed Multiple Tyrosine Kinase Inhibitors

Marcos De Lima, MD, Sairah Ahmed, MD, Elizabeth J Shpall, MD, Gabriela Rondon, MD, Julienne Chen, Glenda G Woodworth, RN, Alexandre Chiattone, MD, Diem Thuy Chu, PA, Uday R Popat, MD, Susanna R Campos, MD, Amin M Alousi, MD, Chitra M Hosing, MD, Simrit Parmar, MD, Partow Kebriaei, MD, Issa F. Khouri, MD, Jorge E. Cortes, Jean-Pierre J Issa, MD, Richard Champlin, MD

Blood (2011) 118 (21): 3106.

https://doi.org/10.1182/blood.V118.21.3106.3106

Published: 2011

Journal Articles

Validation of a DNA Methylation Signature of Favorable Prognosis in Newly Diagnosed Acute Myeloid Leukemia.

Rodolphe F Taby, Sarvari Venkata Yellapragada, Heike Kroeger, Rong He, Steven M. Kornblau, Hagop Kantarjian, Farhad Ravandi, Jaroslav Jelinek, Jean-Pierre J Issa

Blood (2009) 114 (22): 1615.

https://doi.org/10.1182/blood.V114.22.1615.1615

Published: 2009

Journal Articles

Vorinostat in Combination with Decitabine for the Treatment of Relapsed or Newly Diagnosed Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome (MDS): A Phase I, Dose-Escalation Study.

Mark Kirschbaum, MD, Ivana Gojo, MD, Stuart L. Goldberg, MD, Lisa Kujawski, Ehab Atallah, Peter Marks, MD, PhD, Donna Di Gravio, Lisa Pyle, Syed Rizvi, Jean-Pierre J Issa, MD

Blood (2009) 114 (22): 2089.

https://doi.org/10.1182/blood.V114.22.2089.2089

Published: 2009

Journal Articles

Digital Restriction Enzyme Analysis of Methylation (DREAM) by Next Generation Sequencing Yields High Resolution Maps of DNA Methylation.

Jaroslav Jelinek, MD, PhD, Shoudan Liang, PhD, Marcos R. H. Estecio, PhD, Rong He, Yue Lu, PhD, Louis S. Ramagli, PhD, Jean-Pierre J. Issa, MD

Blood (2009) 114 (22): 567.

https://doi.org/10.1182/blood.V114.22.567.567

Published: 2009

Journal Articles

DNA Methylation and Gene Expression Analysis in a Phase II Randomized Study of Decitabine Vs. Decitabine Plus Valproic Acid in MDS and AML.

Ryan J Castoro, Noel J Raynal, Ph.D., Xuelin Huang, Ph.D., Carlos E. Bueso-Ramos, M.D., Ph.D, Guillermo Garcia-Manero, MD, Hagop M. Kantarjian, MD, Jean-Pierre J Issa, MD

Blood (2009) 114 (22): 3808.

https://doi.org/10.1182/blood.V114.22.3808.3808

Published: 2009

Journal Articles

Mechanisms of resistance to 5-aza-2′-deoxycytidine in human cancer cell lines

Taichun Qin, Jaroslav Jelinek, Jiali Si, Jingmin Shu, Jean-Pierre J. Issa

Blood (2009) 113 (3): 659–667.

https://doi.org/10.1182/blood-2008-02-140038

Published: 2009

Journal Articles

Hypermethylation of HOX Genes Is Associated with Longer Survival in Acute Myeloid Leukemia

Jaroslav Jelinek, Heike Kroeger, Rong He, Amanda Saraf, Samantha F Lau, Tuong-Van Nguyen, Michael W Thomas, Elizabeth J Shpall, Steven Kornblau, Carlos Bueso-Ramos, Hagop M Kantarjian, Jean-Pierre J Issa

Blood (2008) 112 (11): 312.

https://doi.org/10.1182/blood.V112.11.312.312

Published: 2008

Journal Articles

Outcome of Patients (pts) with Myelodysplastic Syndrome (MDS) and Chronic Myelomonocytic Leukemia (CMML) Post Decitabine Failure.

Elias Jabbour, Guillermo Garcia-Manero, Jianqin Shan, Susan O’Brien, Jorge Cortes, MD, Farhad Ravandi, Jean-Pierre J Issa, Hagop M Kantarjian

Blood (2008) 112 (11): 1659.

https://doi.org/10.1182/blood.V112.11.1659.1659

Published: 2008

Journal Articles

Aberrant CpG island methylation in acute myeloid leukemia is accentuated at relapse

Heike Kroeger, Jaroslav Jelinek, Marcos R. H. Estécio, Rong He, Kimie Kondo, Woonbok Chung, Li Zhang, Lanlan Shen, Hagop M. Kantarjian, Carlos E. Bueso-Ramos, Jean-Pierre J. Issa

Blood (2008) 112 (4): 1366–1373.

https://doi.org/10.1182/blood-2007-11-126227

Published: 2008

Includes: Supplemental data

Journal Articles

Induction of hypomethylation and molecular response after decitabine therapy in patients with chronic myelomonocytic leukemia

Yasuhiro Oki, Jaroslav Jelinek, Lanlan Shen, Hagop M. Kantarjian, Jean-Pierre J. Issa

Blood (2008) 111 (4): 2382–2384.

https://doi.org/10.1182/blood-2007-07-103960

Published: 2008

Journal Articles

Classifying Leukemias Based on Epigenetic Alterations.

Jaroslav Jelinek, MD, PhD, Marcos R.H. Estecio, PhD, Kimie Kondo, MS, Rong He, MS, Jiri Zavadil, PhD, Jean-Pierre J. Issa, MD

Blood (2007) 110 (11): 2123.

https://doi.org/10.1182/blood.V110.11.2123.2123

Published: 2007

Journal Articles

Safety and clinical activity of the combination of 5-azacytidine, valproic acid, and all- trans retinoic acid in acute myeloid leukemia and myelodysplastic syndrome

Andres O. Soriano, Hui Yang, Stefan Faderl, Zeev Estrov, Francis Giles, Farhad Ravandi, Jorge Cortes, William G. Wierda, Souzanne Ouzounian, Andres Quezada, Sherry Pierce, Elihu H. Estey, Jean-Pierre J. Issa, Hagop M. Kantarjian, Guillermo Garcia-Manero

Blood (2007) 110 (7): 2302–2308.

https://doi.org/10.1182/blood-2007-03-078576

Published: 2007

Journal Articles

Aberrant CpG Island Methylation in AML Is Associated with Disease Progression and Relapse.

Heike Kroeger, MD, Jaroslav Jelinek, MD, PhD, Carlos E. Bueso-Ramos, MD, PhD, Jean-Pierre J. Issa, MD

Blood (2006) 108 (11): 564.

https://doi.org/10.1182/blood.V108.11.564.564

Published: 2006

Journal Articles

RPS19 and JAK2 Are Not Silenced by DNA Methylation in Diamond-Blackfan Anemia.

Jaroslav Jelinek, MD, PhD, Jean-Pierre J. Issa, MD, Rong He, MS, Radek Cmejla, PhD, Jana Cmejlova, PhD, Dagmar Pospisilova, MD PhD

Blood (2006) 108 (11): 1312.

https://doi.org/10.1182/blood.V108.11.1312.1312

Published: 2006

Journal Articles

Hypomethylation Induction and Molecular Response after Decitabine Therapy in Chronic Myelomonocytic Leukemia (CMML).

Yasuhiro Oki, MD, Jaroslav Jelinek, M.D. Ph.D., Hagop M. Kantarjian, M.D., Jean-Pierre J. Issa, M.D.

Blood (2006) 108 (11): 2322.

https://doi.org/10.1182/blood.V108.11.2322.2322

Published: 2006

NARROW

Prospective comparison of outcomes with azacitidine and decitabine in patients with AML ineligible for intensive chemotherapy

Genetic Determinants of Response to Guadecitabine (SGI-110) in AML

Improved Survival for MDS/CMML Patients Treated with the Combination of Decitabine (DAC) and Arsenic Trioxide (ATO) in a Phase II Adaptive Three Arm Randomization Study: DAC Alone Vs. DAC +/- Carboplatin or ATO

Reactivation of the X-Chromosome Genes within PV Clone

The myelodysplastic syndrome as a prototypical epigenetic disease

Sequential Therapy with Allogeneic Transplant Followed by Low-Dose Azacitidine for CML Patients That Failed Multiple Tyrosine Kinase Inhibitors

Validation of a DNA Methylation Signature of Favorable Prognosis in Newly Diagnosed Acute Myeloid Leukemia.

Vorinostat in Combination with Decitabine for the Treatment of Relapsed or Newly Diagnosed Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome (MDS): A Phase I, Dose-Escalation Study.

Digital Restriction Enzyme Analysis of Methylation (DREAM) by Next Generation Sequencing Yields High Resolution Maps of DNA Methylation.

DNA Methylation and Gene Expression Analysis in a Phase II Randomized Study of Decitabine Vs. Decitabine Plus Valproic Acid in MDS and AML.

Mechanisms of resistance to 5-aza-2′-deoxycytidine in human cancer cell lines

Hypermethylation of HOX Genes Is Associated with Longer Survival in Acute Myeloid Leukemia

Outcome of Patients (pts) with Myelodysplastic Syndrome (MDS) and Chronic Myelomonocytic Leukemia (CMML) Post Decitabine Failure.

Aberrant CpG island methylation in acute myeloid leukemia is accentuated at relapse

Induction of hypomethylation and molecular response after decitabine therapy in patients with chronic myelomonocytic leukemia

Classifying Leukemias Based on Epigenetic Alterations.

Safety and clinical activity of the combination of 5-azacytidine, valproic acid, and all- trans retinoic acid in acute myeloid leukemia and myelodysplastic syndrome

Aberrant CpG Island Methylation in AML Is Associated with Disease Progression and Relapse.

RPS19 and JAK2 Are Not Silenced by DNA Methylation in Diamond-Blackfan Anemia.

Hypomethylation Induction and Molecular Response after Decitabine Therapy in Chronic Myelomonocytic Leukemia (CMML).

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only